PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials (Q38831984)

6 September 2017

1 reference

title

PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials (English)

1 reference

6 September 2017

S M Crafton

1

1 reference

6 September 2017

K Bixel

series ordinal

2

1 reference

6 September 2017

J L Hays

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

7 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

142

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

588-596

1 reference

6 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

7 January 2021

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

PARP inhibition: PARP1 and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Poly(ADP-ribose): novel functions for an old molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Targeting the DNA damage response in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

7 January 2021

Recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Meta-analysis of BRCA1 and BRCA2 penetrance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

PARP inhibitors in ovarian cancer: current status and future promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Genetics of endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Essential role for nuclear PTEN in maintaining chromosomal integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Global cancer statistics, 2012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Cisplatin resistance associated with PARP hyperactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.003

10.1016/J.YGYNO.2016.05.003

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference